Baxter International announced the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive. Baxter announced in 2023 plans to create a new Kidney Care company from its Renal Care and Acute Therapies businesses. The new Vantive branding will come into effect when the separation occurs, which is currently expected in the second half of 2024, via either a sale to a private equity investor or a spinoff into a publicly traded company. Until completion of the proposed separation, the Kidney Care business will continue to operate as Baxter. “With the reveal of our mission and logo, we have reached another critical milestone in our journey to establish Vantive. From our legacy as a pioneer in kidney care to our position as a market leader in chronic and acute therapies, we maintain a unique vantage point to help fulfill the pivotal needs of today’s clinicians and patients,” said Chris Toth, executive vice president and group president, Kidney Care at Baxter, who is to serve as Chief Executive Officer of Vantive upon separation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- FDA approves Baxter’s Clinolipid neonatal and pediatric Iindication
- Warner Bros. upgraded, Cerence downgraded: Wall Street’s top analyst calls
- Baxter downgraded to Hold from Buy at TD Cowen
- Baxter International’s Governance and Executive Decisions at 2024 Meeting
- Baxter price target lowered to $44 from $50 at Stifel